Affinium Pharmaceuticals, Inc.

Glaxo Group Limited

Glaxosmithkline LLC

Smithkline Beecham Corporation

Glaxosmithkline Intellectual Property (no.2) Limited

Glaxosmithkline Intellectual Property Limited

Mark Andrew Seefeld

William Henry Miller

Kenneth Allen Newlander

Meagan B Rouse

Irene Nijole Uzinskas

Dalia R Jakas

Walter E Dewolf, Jr

William F Huffman

Walter J Burgess

Dirk Andries Heerding

Jeffrey Michael Axten

Israil Pendrak

Neil David Pearson

Robert A Daines

Nicola Gail Wallis

Timothy Francis Gallagher

Dennis Shinji Yamashita

David John Payne

Ryan Michael Fox

Joshua M West

Simon Peace

Karen Anderson Evans

David G Tew

Martin Brandt

Paul M Keller

Arunbhai H Patel

Kenneth C McNulty

Shannon L Reed

James Lamond Ellis

The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Substituted bridged urea analogs as sirtuin modulators

Invented are novel heterocyclic carboxamide compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Inhibitors of AkT activity

Inhibitors of Akt activity

Invented are novel pyrazole compounds, the use of such compounds as inhibitors of protein kinase B activity and in the treatment of cancer and arthritis.

Compounds of the Formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

FAB I inhibitors

Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections.

Fab I inhibitors

Compounds of the formula (I) are disclosed which are Fab I inhibitors and are useful in the treatment of bacterial infections.

Naphthyridine and quinoline derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Antibacterial agents

Naphthyridine and related derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Compounds of formula (I) and derivatives thereof: compositions containing them, their preparation and their use as antibacterials.

Naphthalene, quinoline, quinoxaline and naphthyridine derivatives useful in the treatment of bacterial infections in mammals, particularly humans, are disclosed herein.

Growing community of inventors

Collegeville, PA, United States of America

Mark Andrew Seefeld